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Three Streptococcus agalactiae (group B streptococci, GBS) immunoreactive proteins:
enolase (47.4 kDa), inosine 5′-monophosphate dehydrogenase (IMPDH) (53 kDa) and
molecular chaperone GroEL (57 kDa) were subjected to investigation. Enolase protein
was described in our previous paper, whereas IMPDH and GroEL were presented for
the first time. The aim of our paper was to provide mapping of specific epitopes, highly
reactive with umbilical cord blood serum. Bioinformatic analyses allowed to select 32
most likely epitopes for enolase, 36 peptides for IMPDH and 41 immunoreactive peptides
for molecular chaperone GroEL, which were synthesized by PEPSCAN. Ten peptides:
two in enolase, one in IMPDH and seven in molecular chaperone GroEL have been
identified as potentially highly selective epitopes that can be used as markers in rapid
immunological diagnostic tests or constitute a component of an innovative vaccine
against GBS infections.
Keywords: Streptococcus agalactiae, immunogenic proteins, epitope mapping, enolase, inosine
5′-monophosphate dehydrogenase IMPDH, molecular chaperone GroEL, diagnostic test
INTRODUCTION
Streptococcus agalactiae (Group B Streptococcus, GBS) is a Gram-positive opportunistic pathogen,
which colonizes the genitourinary and gastrointestinal tracts. However, infections caused by this
bacterium can be dangerous for some patients, including newborns, pregnant women, elderly
patients, diabetics, and immunosuppressed adults (Edwards and Baker, 2005; Rodriguez-Granger
et al., 2012). The percentage of carriers among pregnant European women varies and ranges
from 6.6% in Greece to 36% in Denmark (Tsolia et al., 2003; Hansen et al., 2004). In Poland,
depending on the methodology, up to 30% of pregnant women are estimated to be colonized by
GBS (Brzychczy-Włoch et al., 2012). The risk of transmission to infants during labor reaches 70%
and the probability of infection onset are 2–4 per 1,000 live births (Wessels and Kasper, 1998).
Infections caused by GBS typically take the form of sepsis, pneumonia, or meningitis, which result
in high mortality among infants (Johri et al., 2006). To decrease the growing number of GBS
carriage, since 1996, according to the Centers for Disease Control and Prevention, pregnant women
Dobrut et al. Epitopes of Immunoreactive GBS Proteins
at 35–37 weeks’ gestation are obliged to be screened for GBS
carriage. The detection procedure is based on screening of swabs
taken from the vagina and the rectum, followed by cultivation
on blood agar medium and, if applicable, antibiotic therapy is
introduced. Women who have at least one risk factor from the
CDC’s definition are also prescribed medication (Verani et al.,
2010). An alternative detection method for rapid diagnosis in
pregnant women is based on the PCR protocol. However, its
widespread use is limited because of reagent costs and apparatus
requirements (Verani et al., 2010).
There are numerous immunoreactive GBS proteins
recognized by protective antibodies, which could be markers
of infections caused by S. agalactiae as well as components of
innovative subunit vaccine (Baker and Edwards, 2003). The
best-known immunoreactive GBS proteins are the conservative
and chimeric ones belonging to the alpha-like protein (Alp)
family (Lindahl et al., 2003). Other recently investigated proteins,
including the fibrinogen-binding protein FsbA, peptidase C5a,
the laminin-binding protein Lmb, the conservative protein Sip
and immunogenic bacterial adhesin BibA, demonstrate their
immunoreactive nature and are considered potential vaccine
components (Johri et al., 2006; Rajagopal, 2009; Santillan et al.,
2011; Dzanibe et al., 2016). It was shown that BibA ensures 69%
protection against a lethal challenge dose of GBS serotype-III in
mice models (Santi et al., 2009). Trials on vaccine candidates,
such as the Rib protein, which belongs to the Alp family, or pilus
proteins have been in the preclinical phase (Heath, 2016).
In our previous research, four immunogenic proteins,
including: enolase (47.4 kDa), aldehyde dehydrogenase (50.6
kDa) and, firstly described as being immunogenic in GBS, the
trigger factor (47 kDa) and elongation factor Tu (44 kDa) have
been described (Brzychczy-Wloch et al., 2013). In the present
paper, we identified two more immunogenic proteins: inosine
5′-monophosphate dehydrogenase (IMPDH) (53 kDa) and the
molecular chaperone GroEL (57 kDa).
The aim of this paper was to provide mapping of the
epitopes of three immunoreactive GBS proteins: enolase, IMPDH
and molecular chaperone GroEL using PEPSCAN method. The
epitopes were chemically synthesized on polyethylene pins and
their immunospecificity was tested in the presence of both GBS-
positive and GBS-negative sera. The identified epitopes might be
used in the future as an immunoassay for diagnostic infections
caused by GBS as well as a component of a vaccine against GBS
infections.
MATERIALS AND METHODS
Specimen Collection
The study was approved by Jagiellonian University Bioethical
Committee decision No. KBET/153/B/2014. The study included
34 pregnant women that were patients of the Department of
Clinical Obstetrics and Perinatology, University Hospital in
Krakow, Poland. The consent obtained from the participants
was both informed and written. The inclusion criteria: pregnant
women in the third trimester between 18 and 40 years of age,
a written statement of consent to participate in the study. The
exclusion criteria: pregnant women below 18 and over 40 years
of age, patients with immunodeficiency or autoimmune diseases,
pregnant women with the so-called high-risk pregnancy or with
perinatal complications, preterm delivery, no written consent
to participate in the study or its withdrawal (Pyclik et al.,
2018). The patients included in the study had been divided
into two groups: I. Study group—women with confirmed GBS
colonization (n = 20); II. Control group—women not colonized
by GBS (n= 14).
All the studied patients were tested for the presence of
Streptococcus agalactiae by swabs taken from the lower vagina
(vaginal introitus) and the rectum (anal sphincter) between
the 35th and 37th week of gestation. The samples collected
were cultured and identified in accordance with the Centers for
Disease Control and Prevention guidelines (Verani et al., 2010)
[8].
Umbilical cord blood samples (50ml) were collected
after successful labor. Serum samples isolated from the
blood collected were stored at −70◦C. To qualify serum as
GBS-positive or GBS-negative, the immunoblot with the
presence of GBS immunogenic proteins was done. High
immunoreactivity observed which was measured by absorbance
value in ELISA assay, qualified serum as GBS-positive, whereas
low immunoreactivity qualified serum as GBS-negative.
Additionally, we included venous blood serum from adult
patients to type the most immunoreactive GBS proteins.
Bacterial Strains
S. agalactiae isolates (n = 180) came from the study group of
pregnant women (n = 20), from the patients with urinary tract
infections (UTI) (n = 100) and strains from the pregnant, non-
pregnant patients, and newborns, with different clinical status
(infection and carrier), isolated from various material, such as
blood, vagina and anus swabs, newborn ear swab and, urine
(n= 60) collected within the framework of two projects financed
by the Polish Ministry of Research and Higher Education and
no. 3PO5E08425 and NN401042337 and described in details in
our previous paper (Brzychczy-Wloch et al., 2013). The isolates
tested represented various serotypes (Ia, Ib, II-V), different genes
coding surface of the Alpha-like proteins (bca, alp2, alp3, epsilon,
rib), different macrolide resistance phenotypes (cMLSB, iMLSB,
M), various sequence types (ST) and came from different regions
of Poland. Identification of the bacterial species was performed
by PCR with species-specific primers (Ke et al., 2000). Molecular
characterization of the tested GBS strains was based on the
methodology described in our previous work (Brzychczy-Wloch
et al., 2013). All strains were stored at−70◦C.
Protein Preparation and Analysis
Bacterial isolates were grown on a brain-heart infusion
broth (BHI, Biocorp) for 24 h at 37◦C in aerobic conditions.
Afterwards, cultures in final concentration in solution
A600 nm = 1.0 were subjected to further processing, which
included suspension bacterial pellet in Tris-HCl (Merck)
containing various sodium dodecyl sulfate concentration (1–
2%) (Sigma-Aldrich) or directly in the electrophoresis buffer
according to Heilmann, however, boiling was skipped (Heilmann
et al., 1996). Next, samples were sonicated three times for 5min,
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and centrifuged for 1min in PBS. Proteins were precipitated
from the supernatant obtained using 3 volumes of cold 95%
ethanol (POCH) and incubated at 4◦C overnight. In the next
step, the precipitated proteins were centrifuged, dissolved in
water and their concentration was measured according to the
BCA assay (Smith et al., 1985).
Immunoblotting
The proteins were separated in SDS-PAGE using Prep-
Cell apparatus (Model 491 Bio-Rad) and transferred to
the Immobilon-P membrane (MILIPORE) and subjected
to immunoblotting. The membranes were blocked in PBS
containing 1% of bovine serum albumin (BSA, Thermo Fisher
Scientific) for 1 h, and washed three times with PBS-T [PBS
containing 0.25% Tween (Sigma-Aldrich)]. Next, the membranes
were incubated with human sera, both GBS-positive and GBS-
negative, in 1:300 dilution for 2 h at 37◦C and washed three
times with PBS-T. Afterwards, membranes were incubated
with alkaline phosphatase-conjugated goat anti-human IgG
antibodies (Sigma-Aldrich) diluted 1:5000 for 1 h in the room
temperature. Eventually, after the triple washing with PBST,
membranes were submerged in solution containing nitroblue
tetrazolium (NBT, Roth), 5-bromo-4-chloro-3-indolyl phosphate
(BCIP, Roth), and MgCl2 (POCh) was added for 5 s to visualize
reaction. Bands of interest were cut out from gel and subjected
to digestion by using a proteolytic enzyme such as trypsin
(Roche) to obtain a mixture of peptides. Then, the peptides were
separated by liquid chromatography (LC), and mass fragments
were measured using mass spectrometer LC-MS/MS Orbitrap
(Thermo). Eventually, proteins were identified by comparative
analysis of peptides masses (NCBI, UniProt databases) using
MASCOT (http://www.matrixscience.com/) and statistical
analysis.
Bioinformatics
Among 180 tested GBS isolates, we found that six proteins,
which molecular masses were: 44, 47, 47.4, 50.6, 53, 57 kDa,
which, in immunoblot, showed in every examined strain reacted
with GBS-positive serum, whereas no reactivity was noticed
in presence of GBS-negative serum. Next, bands from three
representative, randomly selected GBS strains were subjected to
bioinformatic analyses were subjected to bioinformatic analyses:
(1) S. agalactiae D129 (serotype III, rib gene, sequence type
ST170) isolated from a patient with urinary tract infection
(UTI); (2) S. agalactiae 1736/08 (serotype V, alp2 gene, cMLSB
phenotype, ermB gene, sequence type ST1), isolated from a
newborn with UTI; (3) S. agalactiae 13793/08 (serotype V,
alp3 gene, cMLSB phenotype, ermB gene, sequence type ST1)
isolated from a newborn with UTI. Each protein demonstrated
high immunoreactivity to GBS-positive sera, however, they
barely reacted with GBS-negative sera. Epitope prediction was
based on amino acid sequence analysis. Prediction of the
protein’s secondary structure, loop regions, burial, and disorder
of amino acids was carried out using Genesilico Metaserver
(https://genesilico.pl/meta2). Antibody Epitope Prediction web
server (http://tools.immuneepitope.org/) was used for epitope
localization within the tested protein. Other methods applied
to predict the most probable epitopes among the investigated
immunoreactive proteins were: Emini Surface Accessibility
Prediction (Emini et al., 1985), Kolaskar & Tongaonkar
Antigenicity (Kolaskar and Tongaonkar, 1990), Bepipred Linear
Epitope Prediction (Larsen et al., 2006). B-cell epitope prediction
was done using another cross method, BCPREDS (http://ailab.ist.
psu.edu/). Protein modeling was based on the crystal structure:
for enolase−1W6T (crystal structure of octameric enolase
from Streptococcus pneumoniae), for IMPDH−1ZFJ (inosine
monophoshate dehydrogenase (IMPDH; EC 1.1.1.205) from
Streptococcus pyogenes), and for molecular chaperone GroEL
- 3RTK (Crystal structure of Cpn60.2 from Mycobacterium
tuberculosis at 2.8A). For more detailed prediction, homology
models made based on 3D structure were done. That allowed
the identification of loop regions on the surface proteins with
disorder tendency which can indicate the most probable epitope
localization. Sequences which had been identified as probable
epitopes by at least two prediction methods and consisted of at
least 6 amino acids were chosen for further analyses.
Peptide Synthesis
Peptide synthesis was carried out according to a slightly modified
Geysen’s procedure (PEPSCAN) (Geysen et al., 1987; Pyclik et al.,
2018) on the NCP Block of 96 hydroxypropylmethacrylate pins
(MIMOTOPES), following the one-plate-one-peptide approach.
Stepwise elongation of peptides from C-end to N-end was
carried out for 6 h or at night in the presence of coupling
solution which contained 60mM Fmoc corresponding to amino
acids diluted in N,N’-dimethylformamide (DMF, Merck KGaA),
two coupling reagents: 65mM of 1-hydroxy-7-azabenzotriazole
(Sigma-Aldrich) and 60mM of diisopropylcarbodiimide (Merck
KGaA) and 10mM bromophenol blue (Sigma-Aldrich). After
completion of the synthesis, deprotection was performed.
Eventually, pins were subjected to disruption in a buffer
containing 1% SDS (Sigma-Aldrich), 0.1% 2-mercaptoethanol
(Thermo Fisher) and 0.1M Na3PO4 (Sigma-Aldrich) of
pH = 7.2, heated to 60◦C in a sonicator (Branson 2210 DTH
Ultrasonic Cleaner) and sonicated for 10min. The disruption
buffer was removed from the pins by submersion in MiliQ
water warmed to 60◦C for 2min, followed by washing in MeOH
(CHEMPUR) warmed to 60◦C for 5min. Afterwards, the pins
were fully dried and kept in dry conditions at 4◦C or−20◦C.
ELISA Assay
The ELISA assay was performed according to the procedure
described in our previous paper (Pyclik et al., 2018). The
procedure was repeated at least three times for every amino
acid sequence, both with GBS-positive and GBS-negative sera.
Epitope detection was carried out in the presence of pooled
both GBS-positive and GBS-negative sera, which resulted from
the limitation of the PEPSCAN method, such as the use of
polyethylene pins in consecutive ELISA assays. Nevertheless,
the specificity of the epitopes identified was confirmed with the
presence of individual sera: 10 for GBS-positive (1/KP, 2/KP,
3/KP, 4/KP, 5/KP, 6/KP, 8/KP, 10/KP, 14/KP, 15/KP) and 5 for
GBS-negative (12/KP, 13/KP, 24/KP, 28/KP, 29/KP), as a negative
control, to confirm their high immunoreactivity to every tested
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serum and to avoid false results, which could occur in the pooled
sera.
Statistical Analysis
Statistical analyses were carried out by Student’s t-test for
independent samples, Dunnett’s multiple comparisons test and
one-way analysis of variance (ANOVA) using IBM SPSS Statistics
24. P values <0.05 were considered statistically significant.
RESULTS
In our previous study at least four immunoreactive proteins,
including enolase, were identified in a pool of sixty genetically
different GBS strains isolated from various infection types
(Brzychczy-Wloch et al., 2013). In this paper, we extended the
number of bacterial samples tested (n = 180) and included
umbilical cord serum (n= 34).
Immunoreactive Proteins Identification and
Epitopes Mapping
Using Heilmann’s modified method, followed by
immunoblotting we isolated and detected at least six
immunoreactive proteins in all GBS strains with molecular
masses ranging between 45 and 57 kDa. Nevertheless, three of
which are studied in this paper: enolase (47.4 kDa), IMPDH
(53 kDa), and molecular chaperone GroEL (57 kDa), in all GBS
strains (Figure 1).
Prediction of the most probable epitopes, based on
bioinformatic analyses, allowed us to choose peptides consisting
of 6–16 amino acids as follows: for enolase protein: 32 peptides,
for IMPDH: 36, and for GroEL: 41. Chemically, epitopes are
defined as a part of the protein consisting of dozens of amino
acids, which is a peptide. The peptides were selected for further
investigation involving the PEPSCAN synthesis (Table 1).
Immunoreactivity of the Epitopes
The ELISA assay performed after synthesis allowed us to
identify 11 peptides with the highest immunoreactivity measured
by absorbance value: two in enolase - 88DRAMIALDGTPN
KG101 (peptide no. 7), 117RAAADYLEVPLYSYLG131 (peptide
no. 9) (Figure 2A); two in IMPDH - 299VVKVGIGPGSIC
TTR313 (peptide no. 23), 382QGRKFKTYRG392 (peptide no.
28) (Figure 3A); and seven in molecular chaperone GroEL—
41KAFGSPLITN50 (peptide no. 3), 362KLQERLAKLA371 (peptide
no. 27), 371AGGVAVIKVGAA382 (peptide no. 28), 381AAT
ETELKEMKLR393 (peptide no. 29), 485MVTTGIIDPVKV496
(peptide no. 37), 495KVTRSALQNA504 (peptide no. 38), 501L
QNAASVASLILTTE515 (peptide no. 39) (Figure 4A). Most
of them, except 88DRAMIALDGTPNKG101 (enolase, peptide
no. 7), 371AGGVAVIKVGAA382 (GroEL, peptide no. 28),
362KLQERLAKLA371 (GroEL, peptide no. 27), and 501LQN
AASVASLILTTE515 (GroEL, peptide no. 39) demonstrated
significant specificity (Table 2). Although the 4VYAREVLDSRG
NPT17 (enolase, peptide no. 1) sequence presented the highest
absorbance, it was dismissed in further analysis due to the highest
standard deviation.
FIGURE 1 | Example results of detection of immunoreactive S. agalactiae
proteins: enolase protein (45 kDa), inosine 5′-monophoshate dehydrogenase
(53 kDa) and molecular chaperone GroEL (57 kDa) separated in SDS-PAGE
and identified by Mascot (Matrix Science, London, United Kingdom). Legend:
Lane 1, marker LMW (low molecular weight) (GE Healthcare Life Sciences);
Lane 2, GBS strain 19-2337/08 isolate from newborn’s mouth smear; Line 3,
GBS isolate 25–CM/47 isolate from neonatal venous blood; Lane 4, GBS
isolate GBS 2 isolated from vagina.
Epitopes Modification on Their
Immunoreactivity
The epitopes listed were modified by cutting off consecutive
amino acids from N-end and C-end to obtain the shortest
immunogenic sequence specifically reactive to the serum
(Figure 5). To sum up, for enolase, among the 36 peptides
tested, two 91MIALDGTPNKG101 and 117RAAADYLEVPLYS
YLG131 demonstrated the highest immunoreactivity to pooled
GBS-positive serum and weak reactivity with pooled GBS-
negative serum (Figures 2B,C, 5). In IMPDH, 40 peptides were
tested, among which two: 299VVKVGIGPGSIC310 and 385RKF
KTYRG392 demonstrated the highest immunoreactivity to the
tested serum (Figure 3C,B, 5). In GroEL, 194 peptides were
tested, among which seven: 43FGSPLITN50, 362KLQE365, 371AG
GVA375, 381AATET385, 485MVTTGIIDPVK495, 496VTRSALQN
A504, and 505SVASLILTTE515 were qualified as potential epitopes
(Figures 4B,C,D, 5). Removing consecutive amino acids of
117RAAADYLEVPLYSYLG131 did not result in an increase in
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TABLE 1 | List of the most likely epitopes of the S. agalactiae immunoreactive proteins: enolase, inosine 5′-monophosphate dehydrogenase (IMPDH) and molecular
chaperone GroEL.
No. Enolase No. Inosine 5′-monophosphate dehydrogenase No. Molecular chaperone GroEL
1 4VYAREVLDSRGNPT17 1 1MSNWDTKFLKKGFT14 1 16VRGVDILADTVKV28
2 17TLEVEVYTESGAFG30 2 15FDDVLLIPAESHVLP29 2 29TLGPKGRNVVLEKA42
3 34VSGASTGEHEAVELR48 3 30NEVDMNTKLA39 3 41KAFGSPLITN50
4 48RDGDKSRYGGLGTQ61 4 44LNIPIITAAMDTVTD58 4 53VTIAKEIELEDHF65
5 61QKAVDNVNNVIAEA74 5 69GGLGIIHKNMSIVD82 5 70AKLVSEVASKTN81
6 75 IIGYDVRDQQAI86 6 83QAEEVRKVKRSEN95 6 82DIAGDGTTTAT92
7 88RAMIALDGTPNKG101 7 96GVIIDPFFLT105 7 91ATVLTQAIVRE101
8 102KLGANAILGVSIAVA116 8 104LTPDNTVSEAEELMQ118 8 105NVTAGANPIGI115
9 117RAAADYLEVPLYSYLG131 9 119NYRISGVPIVET130 9 116RRGIETAVSAAVEEL130
10 135TKVLPT140 10 130TLENRK135 10 132EIAQPVSGKEA142
11 148GSHSDAPIAFQEF161 11 148 ISDYKQLISE157 11 143 IAQVAAVSSRSEKVGE158
12 162MIMPVGAPTFKEAL175 12 162QNLVTAPIGTDLE168 12 165ERVGND170
13 178AEVFHALKKI188 13 178RILHEH183 13 172VITIEESRGME182
14 194LETAVGDEGGFAPK207 14 185 IEKLPLVDDEGR196 14 183TELEVVEGMQFDRGY197
15 208FEGTEDGVETILKAI 222 15 198SGLITIK204 15 198LSQYMVTDNEKMV210
16 224AAGYEAGE231 16 206 IEKVIEFPKAAKDEF213 16 211SELENPYILITD222
17 237GFDCASSEFYD245 17 221GRLLVAGAVG229 17 228 IQEILPLLEEV238
18 243SEFYDAERKVYDYS256 18 230GVTSDTFERA239 18 238VLKTNRPLLIIADD251
19 257KFEGEGGAVRTAAE270 19 239AEALFEA245 19 251DVDGEALPTLVLNK264
20 271QIDYLEELVNKYP283 20 248DAIVIDTA255 20 267GTFNVVAVKAPG278
21 284 IITIEDGMDENDWD297 21 256HGHSAGVLRKI266 21 276APGFGDRRKAM286
22 298GWKALT305 22 284ATAEGARALYDAGVD298 22 288EDIAILTGGTVVTED302
23 308GRVQLVGDDF317 23 299VVKVGIGPGSICTTR313 23 312MQVLGQSAKVTVDKD326
24 328GIKEEAA334 24 314VVAGVGVPQITAIYD328 24 326DSTVIVEGAGDSSAI340
25 334ANSILIKVNQI344 25 329AAAVAREYGKTII341 25 341ANRVAIIK348
26 359EAGYTAVVSHR369 26 345GIKYSGDIVKALAA357 26 349SQMEATTSDFDRE361
27 368HRSGETEDSTI378 27 370AGTDEAPGETEIF382 27 362KLQERLAKLA371
28 378 IADIAVATN386 28 382QGRKFKTYRG392 28 371AGGVAVIKVGAA382
29 386NAGQIKTGSLSR397 29 399MKKGSSDRYFQGSVN413 29 381AATETELKEMKLR393
30 393GSLSRTDRIAKYNQ406 30 414EANKLVPEGIE424 30 403AAVEEGIVSGGGT415
31 404YNQLLRIE411 31 425GRVAYKGSVAD435 31 415TALVNVIEKVAALKL429
32 414LGEVAQYKGIK424 32 436VFQMLGGIR445 32 430NGDEETG436
33 446SGMGYVGAAN455 33 438NIVLRALEEPVRQIA452
34 457KELHDNAQFVEM468 34 452AYNAGYEGSVIIERL466
35 473LKESHPHDVQIT484 35 464ERLKQSE470
36 485NEAPNYSVH493 36 469SEIGTGFNAANGEWV483
37 485MVTTGIIDPVKV496
38 495KVTRSALQNA504
39 501LQNAASVASLILTTE515
40 516AVVANKPEPEAP527
41 427PTAPAMDPSMM537
immunoreactivity in any derivative peptide, therefore, it was
qualified as the epitope (Figure 2C). The peptides listed were
subsequently examined with single sera, both GBS-positive and
GBS-negative, to determine their selectivity. All of the epitopes
tested, except 385RKFKTYRG392, demonstrated significantly high
immunoreactivity to all GBS-positive sera in comparison to
GBS-negative sera (Figure 5), which confirmed their selectivity
and allowed to classify them as epitopes.
Another modification of the peptide synthesis carried
out in this paper was substitution of consecutive amino
acid by alanine and/or glycine. The aim of this modification
was to determine the impact of each amino acid in the
induction of immunoreactivity. Among all (n = 10) of the
tested peptides, only in one epitope of GroEL protein, 485M
VTTGIIDPVKV496, substitution with alanine at position
486 resulted in significant growth of immunoreactivity
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FIGURE 2 | Mapping of epitopes among enolase protein synthesized on polyethylene pins by PEPSCAN. Two peptides (peptides no. 7 and no. 9). (A) showed the
highest absorbance to pooled GBS-positive umbilical cord blood sera and low standard deviation. (B,C) show mean absorbance values of peptides received in
modified synthesis based on cutting off consecutive amino acids from C-end and/or N-end.
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FIGURE 3 | Mapping of epitopes among inosine 5′-monophosphate dehydrogenase synthesized on polyethylene pins by PEPSCAN. Two peptides (peptides no. 23
and no. 28) (A) showed the highest absorbance in the presence of pooled GBS-positive umbilical cord blood sera, thus were chosen for further analyses based on
cutting off consecutive amino acids from C- and N- end (B,C).
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FIGURE 4 | Mapping of epitopes among molecular chaperone GroEL synthesized on polyethylene pins by PEPSCAN. Seven peptides (peptides no. 3, no. 27, no. 28,
no. 29, no. 37, no. 38, and no. 39) (A) showed the highest absorbance in the presence of pooled GBS-positive umbilical cord blood sera. (B–D) show detection of
the shortest peptides highly immunoreactive to GBS-positive sera on the example of peptides no. 27, no. 29, and no. 38.
to GBS-positive serum. Nevertheless, every substitution
with alanine, except isoleucine at position 490, resulted
in higher absorbance in comparison to the initial
epitope.
DISCUSSION
Despite the popularity of intrapartum antibiotic prophylaxis,
infections caused by GBS still result in high morbidity
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TABLE 2 | List of the most immunoreactive peptides of enolase, inosine 5′-monophosphate dehydrogenase and molecular chaperone GroEL (A) and epitopes received
after modification based on cutting-off consecutive amino acids to obtain the shortest immunoreactive sequence (B) and their mean absorbance value measured in
presence of pooled GBS-positive (GBS+) sera and pooled GBS-negative (GBS−) sera.
Protein Peptide A405nm (GBS+) [M ± SD] A405nm (GBS−) [M ± SD] p value
A
Enolase RAMIALDGTPNKG 2.68 ± 0.18 0.06 ±0.05 0.027
RAAADYLEVPLYSYLG 1.81 ± 0.41 0.05 ±0.05 0.103
Inosine 5′-monophosphate dehydrogenase (IMPDH) VVKVGIGPGSICTTR 3.26 ± 0.25 0.92 ±0.20 0.009
QGRKFKTYRG 3.70 ± 0.27 0.47 ±0.61 0.021
Molecular chaperone GroEL KAFGSPLITN 2.27 ± 0.33 1.01 ± 0.11 0.036
KLQERLAKLA 2.27 ± 1.26 0.94 ± 0.13 0.275
AGGVAVIKVGAA 2.32 ± 1.79 0.69 ± 0.00 0.327
AATETELKEMKLR 1.77 ± 0.23 0.68 ± 0.16 0.031
MVTTGIIDPVKV 2.37 ± 0.28 0.92 ± 0.01 0.018
KVTRSALQNA 2.49 ± 0.52 0.63 ± 0.21 0.043
LQNAASVASLILTTE 2.65 ± 1.23 1.01 ± 0.04 0.201
B
Enolase MIALDGTPNKG 2.05 ± 0.50 0.54 ± 0.49 0.002
Inosine 5′-monophosphate dehydrogenase (IMPDH) VVKVGIGPGSIC 1.87 ± 0.30 0.54 ± 0.36 0.001
RKFKTYRG 1.40 ± 0.04 2.42 ± 0.16 0.004
Molecular chaperone GroEL SVASLILTTE 1.50 ± 0.01 0.32 ± 0.10 0.001
FGSPLITN 1.69 ± 0.12 0.83 ± 0.50 0.110
MVTTGIIDPVK 1.93 ±0.30 0.65 ± 0.54 0.004
AGGVA 1.82 ± 0.11 0.78 ± 0.21 0.024
KLQE 1.72 ± 0.05 0.66 ± 0.03 0.002
AATET 1.92 ± 0.28 0.31 ± 0.13 <0.001
VTRSALQNA 1.63 ± 0.26 0.33 ± 0.06 0.080
Statistical significance in immunoreactivity to both GBS-positive and GBS-negative sera described by Student’s t-test.
FIGURE 5 | List of the derivatives of epitopes received in modified synthesis based on cutting off consecutive amino acids. Mean absorbance values were measured
in the presence of single GBS-positive serum (n = 10) and GBS-negative serum (n = 4). Specificity of the epitopes identified was determined by Student’s t-test.
and mortality among newborns. Additionally, the overuse
of antibiotics causes the increase of bacterial resistance to
a growing number of antibiotics (Libster et al., 2012).
Quick diagnostic of GBS infections could maximally shorten
the waiting time for results, which would accelerate the
initiation of targeted antibiotic therapy or, in the case
of a negative result, avoid unnecessary administration of
antibiotics. Currently, there is no quick, effective and precise
diagnostic immunoassay for S. agalactiae infections and/or
carriage. To develop a precise and quick diagnostic test
for pathogenic GBS, an immunoreactive protein specific to
GBS could be used. In our paper, we identified three such
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proteins which were enolase, IMPDH and molecular chaperone
GroEL.
Enolase is a glycolytic enzyme which plays an important
role in bacterial pathogenesis. This anchorless surface protein,
which binds plasminogen, is common for the most of
streptococcal groups (Pancholi and Fischetti, 1998). Even though
immunoreactive nature of GBS enolase has been previously
described, there is still lack of detailed knowledge of its epitopes
(Hughes et al., 2002; Fluegge et al., 2004).
As a result of protein identification followed by the
bioinformatic analysis of enolase, 32 peptides (Table 1) defined
as potential epitopes were subjected to the PEPSCAN method
synthesis (Geysen et al., 1987). The length of the chosen peptides
ranged from 8 to 16 amino acids, and the selection of individual
peptides was determined according to the prediction methods
described above. Introducing this modification allowed to single
out two potential epitopes: peptide no. 7 and peptide no. 9
(Figure 2A), which showed the highest absorbance in reaction
with GBS-positive sera, a very low reactivity level with GBS-
negative sera and a low standard deviation (Table 2). As a
result of modified synthesis, based on cutting off consecutive
amino acids to determine the shortest immunogenic sequence,
derivative of the peptide no. 9, which was 91MIALDGTPN
KG101 demonstrated the highest immunoreactivity to GBS-
positive serum (selectivity p = 0.02) (Figure 5), modification of
peptide no. 7 did not show any growth in immunoreactivity
(Figure 2C). Even though the enolase peptides selected are
common for numerous bacterial species (https://www.ncbi.
nlm.nih.gov/BLAST/), without any doubt, they are specifically
recognized by GBS-positive sera (p= 0.02).
LaFrentz et al. have used enolase as a vaccine component given
to Nile tilapia to protect it from infection caused by Streptococcus
iniae (LaFrentz et al., 2011). Research on epitopes of Clonorchis
sinensis enolase isolated by Wang et al. allowed to identify 10
epitopes and proved their immunogenicity (Wang et al., 2014).
Dutta et al., working on Plasmodium falciparum, identified one
epitope, 104EWGWS108, in enolase and validated its protective
role in mice model (Dutta et al., 2015). In turn, Kolberg et al.
identified another epitope, 55DKSRYGGLG63, in S. pneumoniae
enolase (Kolberg et al., 2006). Nevertheless, the current state of
our knowledge indicates that no one has thus far identified the
same epitopes as the ones described in our work. The differences
among the presented trials may be a confirmation of uniqueness
of the epitopes identified.
The second protein analyzed was inosine 5′-monophosphate
dehydrogenase (IMPDH). This protein is stable tetrameric
purine, which is known for the catalysis of the key stage of de
novo guanine nucleotide synthesis in all organisms, consequently
an essential precursor for DNA and RNA synthesis (Cohen and
Sadee, 1983; Hedstrom, 2009). IMPDH, playing a crucial role in
cell replication is targeted in antiviral, antibacterial or anticancer
therapies, as well as in auto immunological disease treatment
(Ratcliffe, 2006; Hedstrom, 2009; Juda et al., 2014; Shah and
Kharkar, 2015).
The use of the appropriate prediction method preceded by
the bioinformatic analysis of the IMPDH allowed us to identify
36 peptides (Table 1), the sequence length of which oscillated
between 6 and 15 amino acids and presented features of potential
epitopes, whereas 2 of them (Table 2) showed the highest
immunoreactivity. Two peptides: peptide no. 23 and peptide no.
28 were eventually singled out and subjected to further analyses
(Figure 5). Peptide no. 28 presented high immunoreactivity
both to GBS-positive and GBS-negative sera, therefore it was
dismissed from further investigation (Figure 5). The analysis of
the sequences of both peptides (no. 23 and no. 28) in NCBI
BLAST database showed that they are representative of only one
protein, which is IMPDH. Thus far, IMPDH has been examined
for its immunogenicity in other species. Pitarch et al. showed
that IMPDH is one of the immunogenic proteins in Candida
albicans (Pitarch et al., 2001), whereas Duan et al. suggested
its immunogenicity in Streptococcus suis (Duan et al., 2006).
Therefore, it proves that our discovery of the immunogenic role
of this conservative GBS protein is, to our knowledge, pioneering.
The third protein subjected to our investigation was one that
is common in most bacteria, the molecular chaperone GroEL,
which belongs to the chaperonin family. GroEL is a double
ring tetradecamer, consisting of seven subunits in cis and trans
positions, which show ability to form barrel-like structures with
hydrophilic cavities (Zeilstra-Ryalls et al., 1991; Mayhew et al.,
1996). The key role of this protein is its contribution to the
folding of other proteins, therefore it shows both functional
and structural similarity to human Hsp60 (Horwich et al.,
2007). As an equivalent of heat shock protein, GroEL also
shows its immunogenic character (Kaufmann, 1990; Shinnick,
1991), however similarly to IMPDH, its immunogenic role in
S. agalactiae has not been described yet.
In our study, 41 peptides of the GroEL (Table 1) have
been subjected to synthesis, and according to the bioinformatic
analysis conducted, have been singled out as potential epitopes.
The ELISA assay allowed to determine seven polypeptides that
indicated the highest immunoreactivity (Table 2). Peptide no.
29 actually did not show the highest absorbance, nevertheless it
was subjected to further analysis, because its sequence coincided
with peptide no. 28 with two amino acids at positions 381–
382. The aim was to determine whether the epitope coincided
with both peptides. A modified synthesis based on cutting
off the consecutive amino acids allowed to identify seven
potential epitopes (Figure 5). Even though, according to the
literature, peptides with fewer than five amino acids should
not be considered epitopes, we did not dismiss epitope 262KL
QE265 from further analyses, because it was characterized by
high immunoreactivity and selectivity (Benjamini et al., 1997).
Interestingly, derivatives of peptides no. 27 and no. 28 presented
significant specificity to the tested sera. To our best knowledge,
there has not been such detailed research on the epitopes of the
GroEL isolated from GBS thus far. However, results of research
conducted on the whole protein isolated from species such
as Salmonella typhi, Francisella tularensis, or Porphyromonas
gingivalis were previously described (Panchanathan et al., 1998;
Maeda et al., 2000; Valentino et al., 2011). This proves the
immunogenic character of this protein and, at the same time, the
differences between the epitopes identified among this protein
can indicate its species-specificity in the context of the future
rapid diagnostic test for GBS infections. The analysis of the
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chosen epitopes in the NCBI Protein BLAST base showed
that all peptides, except the peptide no. 28 sequence, which
was also identified in the protein adenylosuccinate lyase, were
characteristic exclusively of the GroEL.
We would like to underline that our study concerns on
epitopes not on whole protein. The epitopes (chemically
short peptides) were selected experimentally. They react
selectively only with GBS-positive sera. However, we have made
experiments with additional sera of a carrier Streptococcus
pyogenes (GAS). The results clearly showed no reactivity with
the epitopes comparing to the reactivity with GBS-positive sera.
We would like to emphasize, that the presented results are a
quite new scientific report about the possibility of epitope use
as a very useful tool to develop a new-quality diagnostic test to
detect S. agalactiae bacteria. However, it must be emphasized
that in the test compilation of different epitopes (from different
immunoreactive) proteins will be used and the test condition
needs to be optimized. Received results constitute the basis for
further investigation on highly specific immunoassay.
There is still no universal, rapid, precise diagnostic
immunoassay for identification of infection caused by GBS
as well as recognizing carriage of these bacteria. We believe
that an immunoassay such as ELISA or Western Blot, based on
immunoreactive proteins, or preferably, their highly specific
epitopes, would reduce waiting time for results, which would
allow for immediate application of antibiotic therapy. Therefore,
in our study, we attempted to identify immunoreactive
proteins of GBS and their epitopes selectively reacting with
antibodies from umbilical cord blood. We have identified three
immunogenic proteins and have shown the immunogenic
nature of IMPDH and molecular chaperone GroEL in GBS for
the first time. Additionally, we have selected and synthesized
ten epitopes from the 266 amino acid sequences tested, which
demonstrated selectivity and the highest immunoreactivity to
umbilical cord antibodies. Those features can qualify them as
potential markers for GBS infections as well as components of
the innovative subunit vaccine dedicated to pregnant women,
the elderly and chronic disease patients, which would contribute
to the reduction of the effects caused by S. agalactiae. However,
there is no doubt that extensive advanced research must also be
undertaken.
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